TTX-MC138

DRUG2 trials

Sponsors

QuantumLeap Healthcare Collaborative, TransCode Therapeutics

Conditions

AdenocarcinomaAdenocarcinoma of ColonAdvanced Solid TumorColo-rectal CancerColon CancerColonic NeoplasmsColorectal NeoplasmsER Positive Breast Cancer

Phase 1

PRE-ISPY Phase I/II Oncology Platform Program

RecruitingNCT05868226

QuantumLeap Healthcare CollaborativeHER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer +29

Start: 2023-02-15End: 2031-12-30Target: 280Updated: 2026-09-02

Study of TTX-MC138 in Subjects With Advanced Solid Tumors

Active, not recruitingNCT06260774

TransCode TherapeuticsAdvanced Solid Tumor

Start: 2024-09-05End: 2027-02-01Updated: 2025-10-02

Related Papers

Abstract CT198: Phase 1 clinical trial of a first-in-class antagomir therapeutic against advanced solid tumors

Cancer Research2026-04-17

Abstract PS1-09-17: Phase 1 Clinical Testing of a First-in-Class Antisense Oligonucleotide Therapeutic against Advanced Solid Tumors of Multiple Tissue Origins

Clinical Cancer Research2026-02-17

Abstract PS5-01-24: Evorpacept (ALX-148) combined with trastuzumab deruxtecan in patients with HER2 positive/HER2low metastatic breast cancer (mBC): results from the PRE-ISPY phase Ib trial

Clinical Cancer Research2026-02-17

PRE-ISPY phase I/Ib oncology platform program (PRE-I-SPY-P1).

Journal of Clinical Oncology2024-06-011 citations